 |
DaVita Labs and Myriad RBM Announce Biomarker Research Collaboration
Jun 17, 2013
|
17.6 KB |
|
| |
SALT LAKE CITY, June 17, 2013 (GLOBE NEWSWIRE) -- DaVita Labs, a unit of DaVita HealthCare Partners Inc. (NYSE:DVA) and Myriad RBM, a wholly-owned subsidiary of Myriad Genetics (Nasdaq:MYGN) announced today a research collaboration to conduct protein biomarker discovery research with the goal of developing and commercializing diagnostic tests that ...
|
|
Supreme Court Upholds Myriad's cDNA Patent Claims
Jun 13, 2013
|
16.2 KB |
|
| |
SALT LAKE CITY, June 13, 2013 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) today said the Supreme Court of the United States upheld its patent claims on complementary DNA, or cDNA. However, the Court ruled that five of Myriad's claims covering isolated DNA were not patent eligible. Following today's decision, Myriad has more than 500 val...
|
|
Myriad Genetics to Present at the Goldman Sachs Global Healthcare Conference
Jun 3, 2013
|
11.8 KB |
|
| |
SALT LAKE CITY, June 3, 2013 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) announced today that Peter D. Meldrum, president and CEO, is scheduled to present at the Goldman Sachs 34th Annual Global Healthcare Conference, at 8:40 a.m. Pacific on June 11, 2013 at the Terranea Resort and Spa in Rancho Palos Verdes, California.
The pre...
|
|
AstraZeneca Advances PARP Inhibitor Into Phase 3 Trial With BRACAnalysis(R)
Jun 1, 2013
|
16.1 KB |
|
| |
SALT LAKE CITY, June 1, 2013 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) today announced that AstraZeneca will use Myriad's BRACAnalysis test as a companion diagnostic to stratify patients in AstraZeneca's pivotal Phase 3 clinical studies for olaparib. Myriad has submitted an Investigational Device Exemption (IDE) with the U.S. Food and...
|
|
Myriad Genetics to Present PROLARIS(R) Data at ASCO 2013, Continuing Its Commitment to Cancer Research
May 30, 2013
|
22.3 KB |
|
| |
SALT LAKE CITY, May 30, 2013 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) today announced that Jack Cuzick, Ph.D., of Queen Mary College University of London, will present data from five PROLARIS® clinical studies in patients with prostate cancer at the American Society of Clinical Oncology (ASCO) annual meeting in Chicago.
...
|
|
Myriad Genetics to Present at the Bank of America Merrill Lynch Health Care Conference
May 14, 2013
|
11.8 KB |
|
| |
SALT LAKE CITY, May 14, 2013 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) announced today that Peter D. Meldrum, president and CEO, is scheduled to present at the Bank Of America Merrill Lynch 2013 Health Care Conference, at 10:00 a.m. Pacific on May 16, 2013, at the Encore at the Wynn in Las Vegas, Nevada.
The presentation will ...
|
|
Myriad Genetics Reports Third Quarter Fiscal Year 2013 Results
May 7, 2013
|
26.9 KB |
|
| |
SALT LAKE CITY, May 7, 2013 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) today announced results for its third fiscal quarter and nine months ended March 31, 2013. Revenue for the third fiscal quarter increased 21 percent over the same period in the prior year to $156.5 million. Third fiscal quarter earnings per diluted share were $0.46,...
|
|
Myriad Genetics Announces 2013 Analyst and Investor Day
May 2, 2013
|
11.9 KB |
|
| |
SALT LAKE CITY, May 2, 2013 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) announced today that its Analyst and Investor Day for research analysts and institutional investors will take place on Thursday, May 9, 2013 at 9:00 a.m. EST in New York City. Peter D. Meldrum, president and chief executive officer of Myriad, will host the event th...
|
|
Myriad to Present New Molecular Data for Patients With Prostate Cancer at the American Urological Association 2013 Annual Meeting
May 2, 2013
|
19.0 KB |
|
| |
SALT LAKE CITY, May 2, 2013 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) today highlighted new clinical data on the PROLARIS 46-gene cell cycle progression (CCP) signature in patients with prostate cancer that will be presented at this year's American Urological Association (AUA) in San Diego.
"We have realized for some time that...
|
|
Myriad Genetics to Announce Third Fiscal Quarter 2013 Results on Tuesday, May 7, 2013
Apr 18, 2013
|
13.2 KB |
|
| |
SALT LAKE CITY, April 18, 2013 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) today announced that it will issue financial results for the third fiscal quarter 2013 following the close of market on Tuesday, May 7, 2013.
The Company will also host a conference call on Tuesday, May 7, 2013 at 4:30 P.M. Eastern to review the financial...
|
|
Myriad Adopts RainDance's Thunderstorm Platform for Next-Generation Sequencing Based Hereditary Cancer Panel
Apr 17, 2013
|
17.6 KB |
|
| |
SALT LAKE CITY and LEXINGTON, Mass., April 17, 2013 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) and RainDance Technologies, Inc. today announced that they have entered into a commercial agreement whereby Myriad will adopt RainDance's ThunderStorm™ Target Enrichment System for Myriad's next-generation sequencing based Hereditary Ca...
|
|
Myriad and PharmaMar Announce First Commercial Partnership With Myriad's New HRD Test
Mar 26, 2013
|
16.6 KB |
|
| |
SALT LAKE CITY, March 26, 2013 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) today announced that it has signed an agreement with PharmaMar, a leader in the development of marine-derived drugs. Under the terms of the agreement, Myriad will conduct homologous recombination deficiency (HRD) testing on patients enrolled in PharmaMar's Phase ...
|
|
BRCA Testing Granted Preventive Care Designation Under the Affordable Care Act
Mar 6, 2013
|
16.0 KB |
|
| |
SALT LAKE CITY, March 6, 2013 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) announced today that three federal agencies including the U.S. Department of Health and Human Services, the U.S. Department of Labor, and the U.S. Department of the Treasury have issued a set of FAQs clarifying BRCA testing as a preventive service under the provis...
|
|
Myriad's Prolaris(R) Test Predicts Risk of Prostate Cancer Recurrence in Fourth Peer Reviewed Study
Mar 5, 2013
|
16.0 KB |
|
| |
SALT LAKE CITY, March 5, 2013 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) announced today that a study published in the Journal of Clinical Oncology demonstrated that its Prolaris test, which analyzes the expression level of 46 cell cycle progression genes, accurately predicted the elevated risk for prostate cancer recurrence in 413 men...
|
|
Noridian Prices Molecular Pathology Codes; Myriad Confirms Guidance for Fiscal 2013
Mar 1, 2013
|
15.2 KB |
|
| |
SALT LAKE CITY, March 1, 2013 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) announced today that Noridian Administrative Services LLC ("Noridian"), Medicare administrative contractor for Jurisdiction F which includes Utah, has priced the new molecular pathology codes for calendar year 2013. Since all of Myriad's tests reimbursed by Medica...
|
|
Myriad Genetics Reports Second Quarter Fiscal Year 2013 Results
Feb 5, 2013
|
25.7 KB |
|
| |
SALT LAKE CITY, Feb. 5, 2013 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) today announced results for its second fiscal quarter ended December 31, 2012. Revenue for the second fiscal quarter increased 21 percent over the same period in the prior year to $149.1 million. Second fiscal quarter earnings per diluted share were $0.42, an incr...
|
|
Myriad Genetics to Announce Second Fiscal Quarter 2013 Results on Tuesday, February 5, 2013
Jan 15, 2013
|
12.3 KB |
|
| |
SALT LAKE CITY, Jan. 15, 2013 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) today announced that it will issue financial results for the second fiscal quarter 2013 following the close of market on Tuesday, February 5, 2013.
The Company will also host a conference call on Tuesday, February 5, 2013 at 4:30 P.M. Eastern to review the...
|
|
Myriad Genetics to Present at the 2013 J.P. Morgan Annual Healthcare Conference
Dec 17, 2012
|
12.0 KB |
|
| |
SALT LAKE CITY, Dec. 17, 2012 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) announced today that Peter D. Meldrum, President and CEO, is scheduled to present at the 2013 J.P. Morgan Annual Healthcare Conference, at 9:30 a.m. Pacific Time on Monday, January 7, 2013. The conference is being held at the Westin St. Francis in San Francisco, C...
|
|
Myriad Announces Diabetes Collaboration With Sanofi
Dec 10, 2012
|
18.1 KB |
|
| |
SALT LAKE CITY, Dec. 10, 2012 (GLOBE NEWSWIRE) -- Myriad Genetics (Nasdaq:MYGN) announced today that Myriad RBM, a wholly owned subsidiary of Myriad Genetics, has entered into a research collaboration with Sanofi, a global and diversified healthcare leader, and Population Health Research Institute (PHRI) at Hamilton Health Sciences and McMaster Uni...
|
|
Myriad Genetics' HRD Test Predicts Response to Platinum Therapy in Triple-Negative Breast Cancer
Dec 7, 2012
|
61.2 KB |
|
| |
SALT LAKE CITY, Dec. 7, 2012 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) announced today that a presentation entitled "Homologous recombination deficiency (HRD) score predicts pathologic response following neoadjuvant platinum-based therapy in triple-negative and BRCA1/2 mutation-associated breast cancer (BC)," was presented on Friday, ...
|
|
|
